目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE-RELATED LIMITATIONS
2.6.2 METHODOLOGY-RELATED LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 CLOSED SYSTEM TRANSFER DEVICES MARKET OVERVIEW
4.2 ASIA PACIFIC: CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TECHNOLOGY AND COUNTRY, 2024
4.3 CLOSED SYSTEM TRANSFER DEVICES MARKET: REGIONAL MIX
4.4 CLOSED SYSTEM TRANSFER DEVICES MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS
4.5 CLOSED SYSTEM TRANSFER DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing incidence of cancer and subsequent use of chemotherapy
5.2.1.2 Increasing regulatory approvals for oncology therapeutics
5.2.1.3 Rising awareness about risks associated with handling antineoplastic drugs
5.2.1.4 Stringent regulatory guidelines for handling hazardous medication
5.2.2 RESTRAINTS
5.2.2.1 High implementation costs and limited reimbursements
5.2.2.2 Inconsistent regulatory compliance
5.2.3 OPPORTUNITIES
5.2.3.1 Growth potential across therapeutic applications
5.2.3.2 Rising healthcare expenditure in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Impact of closed system transfer devices on drug quality
5.2.4.2 Low awareness and poor implementation of protective measures
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY COMPONENT
5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & PRODUCT DEVELOPMENT
5.5.2 MATERIAL COMPONENT PROCUREMENT AND MANUFACTURING
5.5.3 MARKETING & SALES, SHIPMENT, AND AFTERSALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Needle-free systems
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Integration of sensors
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Advancements in containments
5.10 INDUSTRY TRENDS
5.10.1 INTEGRATION OF FILTERS IN CLOSED SYSTEM TRANSFER DEVICES
5.10.2 AUTOMATION OF TRANSFER PROCESSES
5.10.3 ADVANCED MATERIALS FOR DURABILITY AND COMPATIBILITY WITH COMPLEX DRUG FORMULATIONS
5.11 PATENT ANALYSIS
5.12 TRADE DATA ANALYSIS
5.12.1 IMPORT DATA
5.12.2 EXPORT DATA
5.13 KEY CONFERENCES AND EVENTS, 2025-2026
5.14 CASE STUDY ANALYSIS
5.14.1 CASE STUDY 1: EXTENSION OF BEYOND-USE DATE OF SINGLE-DOSE VIALS AT MOUNT SINAI HOSPITAL
5.14.2 CASE STUDY 2: ENHANCED SAFETY AND EFFICIENCY OF DRUG COMPOUNDING AT NEBRASKA METHODIST HOSPITAL
5.14.3 CASE STUDY 3: PREVENTION OF MICROBIAL CONTAMINATION DURING SIMULATED WORST-CASE SCENARIOS
5.15 REGULATORY LANDSCAPE
5.15.1 REGULATORY STANDARDS AND APPROVALS
5.15.1.1 US
5.15.1.1.1 USP <800> Regulations
5.15.1.1.2 National Institute for Occupational Safety and Health
5.15.1.1.3 American Society of Health-System Pharmacists
5.15.1.1.4 International Society of Oncology Pharmacy Practitioners
5.15.1.2 European Union
5.15.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.16 PORTER'S FIVE FORCES ANALYSIS
5.16.1 BARGAINING POWER OF SUPPLIERS
5.16.2 BARGAINING POWER OF BUYERS
5.16.3 THREAT OF NEW ENTRANTS
5.16.4 THREAT OF SUBSTITUTES
5.16.5 INTENSITY OF COMPETITIVE RIVALRY
5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 UNMET NEEDS/END-USER EXPECTATIONS
5.19 IMPACT OF GEN AI ON CLOSED SYSTEM TRANSFER DEVICES MARKET
5.19.1 INTRODUCTION
5.19.2 MARKET POTENTIAL OF AI IN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET
5.19.3 AI USE CASES
5.19.4 KEY COMPANIES IMPLEMENTING AI
5.19.5 FUTURE OF GENERATIVE AI IN CLOSED SYSTEM TRANSFER DEVICES MARKET
5.20 IMPACT OF US TARIFF REGULATION ON CLOSED SYSTEM TRANSFER DEVICES MARKET
5.20.1 NORTH AMERICA
5.20.2 EUROPE
5.20.3 ASIA PACIFIC
5.20.4 LATIN AMERICA
5.20.5 MIDDLE EAST & AFRICA

6 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY CLOSING MECHANISM
6.1 INTRODUCTION
6.2 LUER LOCK SYSTEMS
6.2.1 GROWING PREVALENCE OF INJECTABLE DRUGS TO PROPEL MARKET
6.3 PUSH-TO-TURN SYSTEMS
6.3.1 INCREASING FOCUS ON COMPLYING WITH REGULATIONS AND GUIDELINES FOR SAFE HANDLING OF DRUGS TO AID GROWTH
6.4 CLICK-TO-LOCK SYSTEMS
6.4.1 LOW IMPLEMENTATION COST TO CONTRIBUTE TO GROWTH
6.5 COLOR-TO-COLOR ALIGNMENT SYSTEMS
6.5.1 GROWING FOCUS ON CURBING RISK OF MEDICATION ERRORS TO FUEL MARKET

7 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TYPE
7.1 INTRODUCTION
7.2 MEMBRANE-TO-MEMBRANE SYSTEMS
7.2.1 INCREASING FOCUS ON SAFEGUARDING HEALTH AND WELL-BEING OF HEALTHCARE PROVIDERS TO EXPEDITE GROWTH
7.3 NEEDLELESS SYSTEMS
7.3.1 EVOLVING MEDICAL DEVICE TECHNOLOGY LANDSCAPE TO STIMULATE GROWTH

8 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY COMPONENT
8.1 INTRODUCTION
8.2 VIAL ACCESS COMPONENTS
8.2.1 GROWING CONCERNS SURROUNDING HEALTHCARE-ASSOCIATED INFECTIONS TO DRIVE MARKET
8.3 MALE LUERS
8.3.1 NEED TO PREVENT AIR EMBOLISM AND PRESERVE INTEGRITY OF INTRAVENOUS SYSTEMS TO PROMOTE GROWTH
8.4 BAG SPIKES
8.4.1 GROWING FOCUS ON ENHANCED SAFETY, EFFICIENCY, AND PRECISION IN HANDLING AND ADMINISTRATING HAZARDOUS DRUGS TO BOOST MARKET
8.5 FEMALE COMPONENTS
8.5.1 NEED TO PREVENT CONTAMINATION OF DRUGS AND EQUIPMENT TO ENCOURAGE GROWTH
8.6 OTHER COMPONENTS

9 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 DIAPHRAGM-BASED DEVICES
9.2.1 INCREASING USE OF DIAPHRAGM-BASED DEVICES IN CHEMOTHERAPY AND OTHER ONCOLOGY TREATMENTS TO FOSTER GROWTH
9.3 COMPARTMENTALIZED DEVICES
9.3.1 NEED TO MAINTAIN INTEGRITY OF MEDICATIONS DURING TRANSFER TO SUSTAIN GROWTH
9.4 AIR CLEANING/FILTRATION DEVICES
9.4.1 NEED FOR CLEAN AND STERILE ENVIRONMENT WITHIN PHARMACEUTICAL AND HEALTHCARE FACILITIES TO FACILITATE GROWTH

10 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS & CLINICS
10.2.1 GROWING FOCUS ON ENHANCED STAFF AND PATIENT SAFETY IN HEALTHCARE SETTINGS TO BOOST MARKET
10.3 ONCOLOGY CENTERS
10.3.1 NEED TO MINIMIZE RISK OF OCCUPATIONAL EXPOSURE TO AUGMENT GROWTH
10.4 OTHER END USERS

11 CLOSED SYSTEM TRANSFER DEVICES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Rising focus on best practice recommendations and mandates for healthcare workers to aid growth
11.2.3 CANADA
11.2.3.1 Increasing demand for antineoplastic drugs to assist growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Growing emphasis on healthcare protocols to propel market
11.3.3 UK
11.3.3.1 Strict guidelines for handling hazardous drugs to promote growth
11.3.4 FRANCE
11.3.4.1 High healthcare expenditure to accelerate growth
11.3.5 SPAIN
11.3.5.1 Increasing incidence of cancer to favor growth
11.3.6 ITALY
11.3.6.1 Rising geriatric population and subsequent prevalence of chronic diseases to aid growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Established healthcare system and rising geriatric population to drive market
11.4.3 CHINA
11.4.3.1 Large target patient population to stimulate growth
11.4.4 INDIA
11.4.4.1 Rising adoption of chemotherapy procedures to facilitate growth
11.4.5 AUSTRALIA AND NEW ZEALAND
11.4.5.1 Rising incidence of chronic diseases to speed up growth
11.4.6 SOUTH KOREA
11.4.6.1 Shift to aging demography to spur growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Booming healthcare and pharmaceutical sectors to amplify growth
11.5.3 MEXICO
11.5.3.1 Rising initiatives on universal healthcare coverage to support growth
11.5.4 COLOMBIA
11.5.4.1 Growing prioritization of patient and worker safety to bolster growth
11.5.5 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Higher disposable incomes to expedite growth
11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 R&D ASSESSMENT OF KEY PLAYERS
12.6 COMPANY VALUATION AND FINANCIAL METRICES
12.7 BRAND/PRODUCT COMPARISON
12.7.1.1 BD
12.7.1.2 ICU Medical, Inc.
12.7.1.3 B. Braun Melsungen AG
12.7.1.4 JMS Co. Ltd.
12.7.1.5 Baxter
12.7.1.6 EQUASHIELD
12.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.8.1 STARS
12.8.2 EMERGING LEADERS
12.8.3 PERVASIVE PLAYERS
12.8.4 PARTICIPANTS
12.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.8.5.1 Company footprint
12.8.5.2 Region footprint
12.8.5.3 Closing mechanism footprint
12.8.5.4 Type footprint
12.8.5.5 Component footprint
12.8.5.6 Technology footprint
12.8.5.7 End-user footprint
12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.9.1 PROGRESSIVE COMPANIES
12.9.2 RESPONSIVE COMPANIES
12.9.3 DYNAMIC COMPANIES
12.9.4 STARTING BLOCKS
12.9.5 COMPETITIVE BENCHMARKING
12.9.5.1 Detailed list of key startups/SMEs
12.9.5.2 Competitive benchmarking of key startups/SMEs
12.10 COMPETITIVE SCENARIO
12.10.1 PRODUCT LAUNCHES AND APPROVALS
12.10.2 DEALS
12.10.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 BD
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 ICU MEDICAL, INC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Deals
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 B. BRAUN MELSUNGEN AG
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches and approvals
13.1.3.3.2 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 JMS CO. LTD.
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 MnM view
13.1.4.3.1 Right to win
13.1.4.3.2 Strategic choices
13.1.4.3.3 Weaknesses and competitive threats
13.1.5 BAXTER
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.5.4 MnM view
13.1.5.4.1 Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 WEST PHARMACEUTICAL SERVICES, INC.
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Expansions
13.1.7 TERUMO CORPORATION
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Expansions
13.1.8 CARDINAL HEALTH
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.9 EQUASHIELD
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3.1 Product launches and approvals
13.1.9.3.2 Deals
13.1.10 SIMPLIVIA HEALTHCARE LTD.
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3.1 Deals
13.1.11 YUKON MEDICAL
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.12 CODAN MEDIZINISCHE GERATE GMBH
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.13 VYGON
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.14 ELCAM MEDICAL
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.15 PRACTIVET, INC.
13.1.15.1 Business overview
13.1.15.2 Products offered
13.2 OTHER COMPANIES
13.2.1 CARAGEN
13.2.2 CORVIDA MEDICAL
13.2.3 VICTUS
13.2.4 EPIC SYSTEMS CORPORATIONS
13.2.5 ERASER MEDICAL
13.2.6 NEEDLELESS CORPORATION
13.2.7 AMSINO INTERNATIONAL, INC.
13.2.8 INSUNG MEDICAL CO., LTD.
13.2.9 ADVCARE MEDICAL, INC.
13.2.10 SHANDONG ANDE HEALTHCARE APPARATUS CO., LTD.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS